View Future GrowthCentral Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Central Pharmaceuticals은 연평균 11.7%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 3.7%의 비율로 증가했습니다. 매출은 연평균 35.2%의 비율로 감소했습니다.핵심 정보11.65%순이익 성장률11.66%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.00%매출 성장률-35.25%자기자본이익률-2.65%순이익률-60.04%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Jun 10Third quarter 2026 earnings releasedThird quarter 2026 results: Net loss: ৳10.4m (loss narrowed 8.4% from 3Q 2025).공시 • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026공시 • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026공시 • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025공시 • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025공시 • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025모든 업데이트 보기Recent updatesReported Earnings • Jun 10Third quarter 2026 earnings releasedThird quarter 2026 results: Net loss: ৳10.4m (loss narrowed 8.4% from 3Q 2025).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026공시 • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026공시 • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025공시 • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladesh공시 • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025공시 • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025공시 • Jan 23Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025공시 • Nov 09Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024공시 • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladesh공시 • Oct 23Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024New Risk • Oct 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m).Reported Earnings • May 22Third quarter 2024 earnings releasedThird quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.공시 • Apr 28Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024Reported Earnings • Mar 12Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023)Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023).공시 • Jan 26Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Nov 07Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023공시 • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023.공시 • Oct 24Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m).New Risk • Jul 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m).Reported Earnings • Jan 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 04New 90-day high: ৳13.60The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period.Reported Earnings • Dec 30Full year 2020 earnings released: ৳9.24 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 19New 90-day high: ৳13.30The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.공시 • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time.매출 및 비용 세부 내역Central Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DSE:CENTRALPHL 매출, 비용 및 순이익 (BDT Millions)날짜매출순이익일반관리비연구개발비31 Mar 2636-2212031 Dec 2534-2311030 Sep 2534-2912030 Jun 2533-2212031 Mar 25-49-335031 Dec 24-28-4216030 Sep 247-3817030 Jun 2430-4217031 Mar 24112-5930031 Dec 2390-4619030 Sep 2354-4118030 Jun 2329-4419030 Sep 2225-6813030 Jun 2226-6816030 Jun 21148-822030 Jun 20140-1,107611031 Mar 20173-545325031 Dec 192061739030 Sep 192343041030 Jun 193075745031 Mar 193558342030 Sep 183718154030 Jun 183206154031 Mar 182722956030 Sep 1747311262030 Jun 1745610960031 Mar 1748513362031 Dec 1644011662030 Sep 163488159030 Jun 164179868031 Mar 1647710085031 Dec 1555312289030 Sep 1562413593030 Jun 15661143940양질의 수익: CENTRALPHL 은(는) 현재 수익성이 없습니다.이익 마진 증가: CENTRALPHL는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CENTRALPHL는 수익성이 없지만 지난 5년 동안 연평균 11.7%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CENTRALPHL의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CENTRALPHL은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(10.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CENTRALPHL는 현재 수익성이 없으므로 자본 수익률이 음수(-2.65%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/16 10:54종가2026/06/16 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Central Pharmaceuticals Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jun 10Third quarter 2026 earnings releasedThird quarter 2026 results: Net loss: ৳10.4m (loss narrowed 8.4% from 3Q 2025).
공시 • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
공시 • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026
공시 • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025
공시 • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
공시 • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
Reported Earnings • Jun 10Third quarter 2026 earnings releasedThird quarter 2026 results: Net loss: ৳10.4m (loss narrowed 8.4% from 3Q 2025).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
공시 • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026
공시 • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025
공시 • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladesh
공시 • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
공시 • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
공시 • Jan 23Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025
공시 • Nov 09Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
공시 • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladesh
공시 • Oct 23Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024
New Risk • Oct 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m).
Reported Earnings • May 22Third quarter 2024 earnings releasedThird quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
공시 • Apr 28Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024
Reported Earnings • Mar 12Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023)Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023).
공시 • Jan 26Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Nov 07Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023
공시 • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023.
공시 • Oct 24Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023
New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m).
New Risk • Jul 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m).
Reported Earnings • Jan 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 04New 90-day high: ৳13.60The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period.
Reported Earnings • Dec 30Full year 2020 earnings released: ৳9.24 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 19New 90-day high: ৳13.30The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
공시 • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time.